Add to Calendar 5/5/2022 8:30:00 AM 5/5/2022 8:30:00 PM 2022 State of Possible Conference MassBio's annual State of Possible Conference celebrates how the life sciences make the impossible possible. We will tap today’s brightest minds for engaging conversations on the latest developments in our industry, key insights from the past year, and building a better future for patients around the world. This year's conference will explore the theme "The Massachusetts BioPharma Ecosystem in the Post- Covid Era."

Join MassBio and more than 500 attendees for a day of networking, keynotes, and panel discussions from some of the most inspiring voices in the industry, culminating in a reception celebrating the life sciences community. This is our most popular event so you will want to reserve your spot early.
Royal Sonesta Boston, 40 Edwin Land Blvd Cambridge MA 02142
Chief, Division of Geriatric Psychiatry, McLean Hospital
Brent P. Forester, MD, MSc, is the chief of the Division of Geriatric Psychiatry at McLean Hospital, Senior Medical Director for Value-Based Care Solutions, Population Health Management at Mass General Brigham and an Associate Professor of Psychiatry at Harvard Medical School. Dr. Forester is an expert in geriatric psychiatry, specializing in the treatment of older adults with depression, bipolar disorder, and behavioral complications of Alzheimer’s disease and related dementias. He is currently President of the American Association for Geriatric Psychiatry and a distinguished fellow of the American Psychiatric Association. Dr. Forester’s research focuses on studying novel treatment interventions to manage behavioral complications of dementia such as agitation and aggression. Dr. Forester also leads a Mass General Brigham system-wide initiative to enhance the assessment and treatment of individuals with dementia, while supporting family caregivers, in primary care settings. Finally, Dr. Forester and his research team use brain imaging techniques and careful clinical assessment to better understand the causes of dementia, depression and bipolar disorder in later life and to identify promising new targets for effective treatments.

Brought to you by